Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High – Still a Buy?

Takeda Pharmaceutical Co. (NYSE:TAK)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $17.45 and last traded at $17.44, with a volume of 645292 shares. The stock had previously closed at $17.23.

Analysts Set New Price Targets

Several brokerages recently commented on TAK. Morgan Stanley assumed coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating for the company. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65. The firm has a market cap of $56.42 billion, a P/E ratio of 73.88 and a beta of 0.02. The company’s 50-day moving average is $15.53 and its two-hundred day moving average is $14.85.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). The firm had revenue of $7.76 billion for the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%. Sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently modified their holdings of the business. Private Trust Co. NA boosted its stake in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the last quarter. Twin Peaks Wealth Advisors LLC acquired a new position in Takeda Pharmaceutical in the second quarter valued at $28,000. Evelyn Partners Investment Management LLP boosted its position in Takeda Pharmaceutical by 163.4% during the second quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock valued at $39,000 after acquiring an additional 1,560 shares during the last quarter. True Wealth Design LLC grew its holdings in Takeda Pharmaceutical by 1,262.3% during the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock worth $40,000 after acquiring an additional 2,512 shares during the period. Finally, NewSquare Capital LLC lifted its stake in shares of Takeda Pharmaceutical by 182.4% in the 2nd quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock valued at $53,000 after purchasing an additional 2,229 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.